Alterations in alcohol consumption, withdrawal seizures, and monoamine transmission in rats treated with phentermine and 5-hydroxy-L-tryptophan

Synapse

Volumn 59, Issue 5, 2006, Pages 277-289

  Halladay, A K ^a   Wagner, G C ^a   Sekowski, A ^a   Rothman, R B ^b   Baumann, M H ^b   Fisher, Hans ^a  

^a RUTGERS UNIVERSITY   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Alcohol consumption; Alcohol withdrawal; Animal model; Dopamine; Microdialysis; Neurochemistry; Serotonin

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 5 HYDROXYINDOLEACETIC ACID; 5 HYDROXYTRYPTOPHAN; ALCOHOL; BENSERAZIDE; DOPAMINE RECEPTOR STIMULATING AGENT; FENFLURAMINE; HOMOVANILLIC ACID; MONOAMINE; PHENTERMINE; SEROTONIN; SEROTONIN AGONIST;

ALCOHOL CONSUMPTION; ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANOREXIA; ARTICLE; AUTOPSY; CONTROLLED STUDY; CORPUS STRIATUM; DIET; DRUG EFFECT; DRUG POTENTIATION; FOOD INTAKE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPERPHAGIA; MALE; MICRODIALYSIS; MONOAMINE RELEASE; MONOTHERAPY; NEUROCHEMISTRY; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT; RAT STRAIN; SEROTONIN RELEASE; STATISTICAL ANALYSIS; WITHDRAWAL SEIZURE;

5-HYDROXYTRYPTOPHAN; ALCOHOL DRINKING; ALCOHOL WITHDRAWAL SEIZURES; ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; BIOGENIC MONOAMINES; BRAIN CHEMISTRY; CENTRAL NERVOUS SYSTEM DEPRESSANTS; CENTRAL NERVOUS SYSTEM STIMULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ETHANOL; MALE; PHENTERMINE; RATS; RATS, LONG-EVANS; TIME FACTORS;

EID: 33144475006     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/syn.20239     Document Type: Article

References (54)

1. Alvarado R, Contreras S, Segoivia-Riquelme N, Mardones J. 1990. Effects of serotonin uptake blockers and 5-hydroxytryptophan on the voluntary consumption of ethanol, water and solid food by UChA and UChB rats. Alcohol 7:315-319.
2. Amer A, Breu J, McDermott J, Wurtman RJ, Maher TJ. 2004. 5-Hydroxy-L-tryptophan suppresses food intake in food-deprived and stressed rats. Pharmacol Biochem Behav 77:137-143.
3. Arai R, Karasawa N, Nagatsu T, Nagatsu I. 1995. Exogenous L-5-hydroxytryptophan is decarboxylated in neurons of the substantia nigra pars compacta and locus coeruleus of the rat. Brain Res 669:145-149.
4. Baumann MH, Ayestas MA, Dersch CM, Brockington A, Rice KC, Rothman RB. 2000. Effects of phentermine and fenfluramine on extracellular dopamine and serotonin in rat nucleus accumbens: therapeutic implications. Synapse 36:102-113.
5. Caetano R, Clark CL, Greenfield TK. 1998. Prevalence, trends and incidence of alcohol withdrawal symptoms. NIAAA Epidemiol Bull 22:73-79.
6. Cangiano C, Ceci F, Cascino A, Del Ben M, Laviano A, Muscaritoli M, Antonucci R, Rossi-Fanelli F. 1992. Eating behavior and adherence to dietary prescription in obese adult subjects treated with 5-hydroxytryptophan. Am J Clin Nutr 56:863-867.
7. Connolly HM, McGoon MD. 1999. Obesity drugs and the heart. Curr Probl Cardiol 24:745-792.
8. Darmani NA, Johnson JC. 2004. Central and peripheral mechanisms contribute to the antiemetic actions of delta-9-tetrahydrocannabinol against 5-hydroxytryptophan-induced emesis. Eur J Pharmacol 488:201-212.
9. Das YT, Bagchi M, Bagchi D, Preuss HG. 2004. Safety of 5-hydroxy-L-tryptophan. Toxicol Lett 150:111-122.
10. DeMontis MG, Grappi S, Gambarana C, Leggio B, Nanni G, Scheggi S, Tagliamonte A. 2004. Sardinian alcohol-preferring rats show low 5-HT extraneuronal levels in the mPFC and no habituation in monoaminergic response to repeated ethanol consumption in the NAcS. Brain Res 1006:18-27.
11. DiChiara G, Imperato A. 1988. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Nat Acad Sci USA 85:5274-5287.
12. Gartside SE, Cowen PJ, Sharp T. 1992. Effect of 5-hydroxy-L-tryptophan on the release of 5-HT in rat hypothalamus in vivo as measured by microdialysis. Neuropharmacol 31:9-14.
13. Geller I, Hartmann RJ, Messiha FS. 1981. Blockade of 5-HTP reduction of ethanol drinking with the decarboxylase inhibitor, Ro 4-4602. Pharmacol Biochem Behav 15:871-874.
14. Halladay AK, Fisher H, Wagner GC. 1998. Interaction of phentermine plus fenfluramine: neurochemical and neurotoxic effects. Neurotoxicol 19:177-184.
15. Halladay AK, Fisher H, Wagner GC. 2000. Effects of phentermine and fenfluramine on alcohol consumption and alcohol withdrawal seizures in rats. Alcohol 20:19-29.
16. Hashiguti H, Nakahara D, Maruyama W, Naoi M, Ikeda T. 1993. Simultaneous determination of in vivo hydroxylation of tyrosine and tryptophan in rat stratum by microdialysis HPLC: relationship between dopamine and serotonin biosynthesis. J Neural Trans Gen Sect 93:213-223.
17. Hitzig P. 1993. Combined dopamine and serotonin agonists: a synergistic approach to alcoholism and other addictive behaviors. Md Med J 42:153-156.
18. Hitzig P. 1994. Combined serotonin and dopamine indirect agonists correct alcohol craving and alcohol-associated neuroses. J Subst Abuse Treat 11:489-490.
19. Katner SN, Weiss F. 2001. Neurochemical characteristics associated with ethanol preference in selected alcohol-preferring and -non-preferring rats: a quantitative microdialysis study. Alcohol: Clin Exp Res 25:198-205.
20. Kato N, Murase Y. 1975. A histochemical study on the central effect of monamine precursors. Folia Psychiatr Neurol Jpn 29:190-195.
21. Koob GF, Roberts AJ, Schulteis G, Parsons LH, Heyser CJ, Hyytia P, Merlo-Pich E, Weiss F. 1998. Neurocircuitry targets in ethanol reward and dependence. Alcohol: Clin Exp Res 22:3-9.
22. Leadbetter MW, Parmar SS. 1989. Serotonin as a facilitory neurotransmitter in the anticonvulsant activity of methaqualone. Physiol Behav 46:105-106.
23. Li XM, Perry KW, Fuller RW 1996. On the in-vivo modulation of neostriatal dopamine release by fluoxetine and 5-hydroxy-L-tryptophan in conscious rats. J Pharm Pharmacol 48:825-828.
24. Loscher W, Czuczwar SJ. 1985. Evaluation of the 5-hydroxytryptoamine receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin in different rodent models of epilepsy. Neurosci Lett 2:201-206.
25. Loscher W, Pagliusi SR, Muller F. 1984. L-5-hydroxytryptophan. Correlation between anticonvulsant effect and increases in levels of 5-hydroxyindoles in plasma and brain. Neuropharmacol 23:1041-1048.
26. Lynn-Bullock CP, Welshhans K, Pallas SL, Katz PS. 2004. The effect of oral 5-HTP administration on 5-HTP and 5-HT immunoreactivity in monoaminergic brain regions of rats. J Chem Neuroanat 27:129-138.
27. Minano FJ, Myers RD. 1989. Inhibition of brain dopa-decarboxylase RO4-4602 infused ICV blocks alcohol drinking induced in rats by cyanamide. Psychopharmacology 98:176-182.
28. Mirovsky Y, Yu L, Wagner GC, Sekowski A, Goldberg M, Fisher H. 1995a. Novel synergistic treatment of ethanol withdrawal seizures in rats with dopamine and serotonin agonists. Alcohol: Clin Exp Res 19:160-163.
29. Mirovsky Y, Wagner GC, Sekowski A, Goldberg M, Fisher H. 1995b. Simultaneous changes in striatal dopamine, serotonin, and metabolites after withdrawal seizures in rats from dependence on alcohol. Alcohol 112:251-256.
30. Munzar P, Baumann MH, Shoaib M, Goldberg SR. 1999. Effects of dopamine and serotonin-releasing agents on methamphetamine discrimination and self-administration in rats. Psychopharmacology 141:287-296.
31. Parsons LH, Justice JB, Jr. 1993 Perfusate serotonin increases extracellular dopamine in the nucleus accumbens as measured by in vivo microdialysis. Brain Res 606:195-199.
32. Paxinos G. 1982: The Rat Brain in Stereotaxic Coordinates. New York: Academic Press.
33. Pletcher A, Gey KF. 1963. The effect of a new decarboxylase inhibitor on endogenous and exogenous monoamines. Biochem Pharmacol 12:223-228.
34. Prow MR, Lancashire B, Aspley S, Heal DJ, Kilpatrick IC. 2001. Additive effects on rat brain 5HT release of combining phentermine with dexfenfluramine. Int J Obes Relat Metab Dis 25:1450-1453.
35. Roth JD, Rowland NE. 1998. Efficacy of administration of dexfenfluramine and phentermine, alone and in combination, on ingestive behavior and body weight in rats. Psychopharmacology 137:99-106.
36. Rothman RB, Baumann MH. 2002a. Serotonin releasing agents. Neurochemcial, therapeutic and adverse effects. Pharmacol Biochem Behav 71:825-836.
37. Rothman RB, Baumann MH. 2002b. Therapeutic and adverse actions of serotonin transporter substrates. Pharmacol Ther 95:73-88.
38. Rothman RB, Blough BE, Woolverton WL, Anderson KG, Negus SS, Mello NK, Roth BL, Baumann MH. Development of a rationally-designed, low abuse potential, biogenic amine releaser that suppresses cocaine self-administration. J Pharmacol Exp Ther, in press.
39. Saglam E, Uzbay IT, Kayir H, Celik T, Beyazyurek M. 2004. Effects of venlafaxine on ethanol withdrawal syndrome in rats. Fund Clin Pharmacol 18:693-698.
40. Smith AD, Weiss F. 1999. Ethanol exposure differentially alters central monamine neurotransmission in alcohol-preferring versus nonpreferring rats. J Pharmacol Exp Ther 288:1223-1228.
41. Sriram K, Benkovic SA, Miller DB, O'Callaghan JP. 2002. Obesity exacerbates chemically induced neurodegeneration. Neuroscience 115:1335-1346.
42. Thielen RJ, Engleman EA, Rodd ZA, Murphy JM, Lumeng L, Li T-K, McBride WJ. 2004. Ethanol drinking and deprivation alter dopaminergic and serotonergic function in the nucleus accumbens of alcohol-preferring rats. J Pharmacol Exp Ther 309:216-225.
43. Treseder SA, Rose S, Summo L, Jenner P. 2003. Commonly used L-amino acid decarboxylase inhibitors block monoamine oxidase activity in the rat. J Neural Trans 110:229-238.
44. Ulus IH, Maher TJ, Wurtman RJ. 2000. Characterization of phentermine and related compounds as monoamine oxidase (MAO) inhibitors. Biochem Pharmacol 59:1611-1621.
45. Uzbay IT, Usanmaz SE, Tapanyigit EE, Aynacioglu S, Akarsu ES. 1998. Dopaminergic and serotonergic alterations in the rat brain during ethanol withdrawal: association with behavioral signs. Drug Alcohol Depend 53:39-47.
46. Uzbay IT, Saglam E, Kayier H, Celik T, Beyazyurek M. 2004. Effects of fluoxetine on ethanol withdrawal syndrome in rats. J Psychiatr Res 38:445-450.
47. Weiss F, Parson LH, Schulteis G, Hyytia P, Lorang MT, Bloom FE, Koob GF 1996. Ethanol self-administration restores withdrawal-associated deficiencies in accumbal dopamine and 5-hydroxytryptamine release in dependent rats. J Neurosci 16:3474-3485.
48. Yan QS, Jobe PC, Dailey JW. 1994. Evidence that a serotonergic mechanism is involved in the anticonvulsant effect of fluoxetine in genetically epilepsy-prone rats. Eur J Pharmacol 252:105-112.
49. Yoshimoto K, McBride WJ, Lumeng L, Li TK. 1991. Alcohol stimulates the release of dopamine and serotonin in the nucleus accumbens. Alcohol 9:17-22.
50. Yu L, Fisher H, Sekowski A, Wagner GC. 1997. Amphetamine and fenfluramine suppress ethanol intake in ethanol-dependent rats. Alcohol 14:45-48.
51. Yu L, Fisher H, Wagner GC. 2000. Monoaminergic changes associated with audiogenic seizures in ethanol-dependent rats. Prog Neuropsychopharmacol Biol Psychiatry 24:1379-1392.
52. Zabik JE, Roache JD. 1983. 5-hydroxy-tryptophan-induced conditioned taste aversion to ethanol in the rat. Pharmacol Biochem Behav 18:785-790.
53. Zabik JE, Sprague JE, Binkerd K. 1994. Central and peripheral components of the inhibitory actions of 5-HTP on ethanol consumption in the rat. Pharmacol Biochem Behav 43:547-551.
54. Zmilacher K, Battegay R, Gastpar M. 1988. L-5-hydroxytryptophan alone and in combination with a peripheral decarboxylase inhibitor in the treatment of depression. Neuropsychobiol 20:28-35.